Clinical trial · Observational
Helicobacter Pylori and Proton Pump Inhibitor
Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor
NCT02449941CI-TRIAL-00025014completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to know the distribution of HP in stomach before use of PPI, during use of PPI, and after stop of PPI.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Helicobacter Infections | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PPI (proton pump inhibitor) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Helicobacter pylori(HP) positive
- description
- Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
- interventionNames
- Drug: PPI (proton pump inhibitor)
Primary outcomes (1)
- measure
- Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor
- timeFrame
- Change in the distribution of Helicobacter Pylori(HP) at 4 months.
Secondary outcomes (1)
- measure
- Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach
- timeFrame
- Change in the distribution of Helicobacter Pylori(HP) at 4 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients who are indicated to endoscopic resection due to gastric neoplasm 2. Aged between 19 to 65 years 3. Informed consent Exclusion Criteria: 1. Previous history of HP eradication 2. Previous history of PPI use within 6 months 3. No HP infection
References
Publications (1)
- DERIVEDGong EJ, Kim DH, Ahn JY, Na HK, Jung KW, Lee JH, Choi KD, Song HJ, Lee GH, Jung HY, Park Y, Kim MJ. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy. Digestion. 2020;101(3):279-286. doi: 10.1159/000499424. Epub 2019 May 8. PMID 31067538